ClinicalTrials.gg

Program

cabotegravir

Also written as “CAB LA”, “GSK1265744” and “Cabotegravir - Injectable Suspension (CAB LA)”.

Its studies are mostly in HIV Infections · Infections · Acquired Immunodeficiency Syndrome · HIV-Associated Lipodystrophy Syndrome, led by 2 companies.

Furthest: phase 4, since May 10, 202241 company-led studies, 8 open or runningNext primary completion: Mar 8, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline408 open or runningphase 4since May 10, 2022Apr 10, 2008Mar 8, 2027phase 1 · NCT06786520
Johnson & Johnson10 open or runningphase 1since Nov 2, 2021Nov 2, 2021none ahead

Also a collaborator on its studies: ppd-development-lp and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Apr 10, 2008.

  1. May 18, 2020Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04399551 · 437 enrolled · Belgium, France, Germany and more
  2. Jul 20, 2020Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT04484337 · 138 enrolled · United States, New Zealand
  3. Sep 1, 2020Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04542070 · 687 enrolled · United States, Australia, Austria and more
  4. Nov 2, 2021Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT05112939 · 126 enrolled · United States, Netherlands
  5. May 10, 2022Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT05374525 · 287 enrolled · United States
  6. Aug 22, 2022Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT05514509 · 295 enrolled · United States
  7. May 31, 20232 phase 3 studies in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT05896761, NCT05896748
  8. Jun 13, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05917509 · 171 enrolled · United States, Argentina, Canada and more
  9. Aug 31, 2023Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06033547 · 56 enrolled · United States
  10. Nov 10, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT06134362 · 2,998 enrolled · Argentina, Botswana, Brazil and more
  11. Dec 17, 2024Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT06741397 · 229 enrolled · United States, Puerto Rico
  12. Jan 15, 2025Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06786520 · 69 enrolled · United States
  13. Apr 11, 2025Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06970223 · 65 enrolled · United States
  14. Nov 27, 2025Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT07275606 · 44 planned · South Africa

Ahead

  1. Mar 8, 2027Primary completion: phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06786520
  2. Mar 14, 2029Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT06134362
  3. Oct 10, 2029Primary completion: phase 2 study in HIV InfectionsGlaxoSmithKline · NCT07275606

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

All 41 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07275606HIV Infections · South Africa2RecruitingGlaxoSmithKlineOct 10, 202944
NCT06970223HIV Infections · United States1Active, not recruitingGlaxoSmithKlineJul 15, 202565
NCT06786520HIV Infections · United States1Active, not recruitingGlaxoSmithKlineMar 8, 202769
NCT06741397HIV Infections · United States, Puerto Rico2Active, not recruitingGlaxoSmithKlineSep 9, 2026229
NCT06134362HIV Infections · Argentina, Botswana, Brazil and more3Active, not recruitingGlaxoSmithKlineMar 14, 20292,998
NCT06033547HIV Infections · United States1CompletedGlaxoSmithKlineJul 25, 202556
NCT05917509HIV Infections · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineSep 16, 2025171
NCT05896761Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineAug 23, 2022118
NCT05896748Acquired Immunodeficiency Syndrome · United States, Canada, Japan and more3CompletedGlaxoSmithKlineSep 14, 202394
NCT05514509HIV Infections · United States4CompletedGlaxoSmithKlineSep 2, 2025295
NCT05374525HIV Infections · United States4CompletedGlaxoSmithKlineAug 8, 2024287
NCT05112939Healthy · United States, Netherlands1CompletedJohnson & JohnsonMay 23, 2024126
NCT04542070HIV Infections · United States, Australia, Austria and more3CompletedGlaxoSmithKlineJul 13, 2022687
NCT04484337HIV Infections · United States, New Zealand1CompletedGlaxoSmithKlineMay 5, 2023138
NCT04399551HIV Infections · Belgium, France, Germany and more3CompletedGlaxoSmithKlineMar 7, 2022437
NCT04371380HIV Infections · United States1CompletedGlaxoSmithKlineDec 26, 202115
NCT03639311HIV Infections · United States, Canada2CompletedGlaxoSmithKlineDec 11, 201997
NCT03299049HIV Infections · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineJun 6, 20191,049
NCT03149848Infections · United Kingdom1CompletedGlaxoSmithKlineSep 6, 201715
NCT02951052Infections · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineMay 29, 2018618
NCT02938520HIV Infections · United States, Canada, France and more3Active, not recruitingGlaxoSmithKlineAug 30, 2018631
NCT02799264Infections · United States1CompletedGlaxoSmithKlineAug 201624
NCT02478463Infections · United States1CompletedGlaxoSmithKlineJul 25, 201919
NCT02354950HIV Infections · United States1CompletedGlaxoSmithKlineSep 16, 201616
NCT02354937Infections · United States1CompletedGlaxoSmithKlineNov 1, 201616
NCT02345707Infections · United States1CompletedGlaxoSmithKlineJun 201537
NCT02159131Infections · United Kingdom1CompletedGlaxoSmithKlineDec 201420
NCT02120352Infections · United States, Canada, France and more2CompletedGlaxoSmithKlineAug 13, 2015309
NCT02059031Infections · United States1CompletedGlaxoSmithKlineJun 201424
NCT02027454Infections · United States1CompletedGlaxoSmithKlineJun 201442
NCT01848340HIV-Associated Lipodystrophy Syndrome · United States1CompletedGlaxoSmithKlineJul 201316
NCT01754116Infections · United States1CompletedGlaxoSmithKlineApr 201443
NCT01648257Infections · United States1CompletedGlaxoSmithKlineNov 201218
NCT01641809Infections · United States, Canada2CompletedGlaxoSmithKlineOct 10, 2013244
NCT01593046Infections · United States1CompletedGlaxoSmithKlineNov 201343
NCT01467531Infections · United States1CompletedGlaxoSmithKlineFeb 201228
NCT01756131Infections1CompletedGlaxoSmithKlineDec 201272
NCT00920426Infections · United States2CompletedGlaxoSmithKlineAug 13, 20099
NCT00920296Infections · United States1CompletedGlaxoSmithKlineSep 200912
NCT00812318HIV Infections · United States1CompletedGlaxoSmithKlineAug 200845
NCT00659191HIV Infections · United States1CompletedGlaxoSmithKlineNov 200858

How it is read

Names in the registry

  • “CAB LA”, 7 entries
  • “GSK1265744”, 5 entries
  • “Cabotegravir - Injectable Suspension (CAB LA)”, 3 entries
  • “Cabotegravir (CAB) tablet”, 2 entries
  • “Cabotegravir Injectable Suspension”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.